类器官分析识别胰腺癌化疗常见应答者
该研究构建了胰腺癌患者来源类器官库,重现了原发肿瘤的突变谱和转录亚型。类器官对标准化疗和试验药物表现出异质性反应,其治疗特征与患者结局平行,并衍生出预测化疗敏感性的基因表达特征。
要点
- 胰腺癌类器官库可重现原发肿瘤的突变谱与转录亚型。
- 类器官治疗特征与患者结局平行,支持纵向评估化疗敏感性。
- 基于类器官的基因表达特征可预测辅助和晚期化疗应答。
核心结论
- 类器官的分子与治疗分析可能预测临床反应并支持前瞻性治疗选择。
研究设计与样本
- 研究构建了胰腺癌患者来源类器官库,重现原发胰腺癌的突变谱和转录亚型。
主要发现
- 类器官对标准化疗和试验药物表现出异质性反应。
- 以个案研究方式发现类器官治疗特征与患者结局平行。
- 类器官支持纵向评估化疗敏感性和评估同步转移灶。
- 衍生出基于类器官的化疗敏感性基因表达特征,预测辅助和晚期化疗应答改善。
- 利用靶向药物治疗分析为化疗难治性类器官提名替代治疗策略。
临床怎么用
- 联合分子与治疗分析类器官可能预测临床反应并支持前瞻性治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pancreatic cancer is the most lethal common solid malignancy. Systemic therapies are often ineffective, and predictive biomarkers to guide treatment are urgently needed. We generated a pancreatic cancer patient-derived organoid (PDO) library that recapitulates the mutational spectrum and transcriptional subtypes of primary pancreatic cancer. New driver oncogenes were nominated and transcriptomic analyses revealed unique clusters. PDOs exhibited heterogeneous responses to standard-of-care chemotherapeutics and investigational agents. In a case study manner, we found that PDO therapeutic profiles paralleled patient outcomes and that PDOs enabled longitudinal assessment of chemosensitivity and evaluation of synchronous metastases. We derived organoid-based gene expression signatures of chemosensitivity that predicted improved responses for many patients to chemotherapy in both the adjuvant and advanced disease settings. Finally, we nominated alternative treatment strategies for chemorefractory PDOs using targeted agent therapeutic profiling. We propose that combined molecular and therapeutic profiling of PDOs may predict clinical response and enable prospective therapeutic selection.Significance: New approaches to prioritize treatment strategies are urgently needed to improve survival and quality of life for patients with pancreatic cancer. Combined genomic, transcriptomic, and therapeutic profiling of PDOs can identify molecular and functional subtypes of pancreatic cancer, predict therapeutic responses, and facilitate precision medicine for patients with pancreatic cancer. Cancer Discov; 8(9); 1112-29. ©2018 AACR.See related commentary by Collisson, p. 1062This article is highlighted in the In This Issue feature, p. 1047.
引用
- Tiriac H, Belleau P, Engle DD, et al. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov. 2018. PMID: 29853643. doi:10.1158/2159-8290.CD-18-0349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。